Skip to content
Buy This GLP
← Research
Evidence

How Much Are Countries Spending on GLP-1 Drugs?

Croatia estimated €42.07 million in GLP-1 spending in 2024. Studies from Australia and the US answer separate questions about eligibility and overall costs.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
GLP-1 share of non-insulin diabetes drugs, Croatia 2024of standardized volume16.1%of estimated spending42.7%€42.07 million in estimated spending.Volume measured in defined daily doses.

Croatia estimated spending €42.07 million on GLP-1 drugs in 2024 [1]. That was 42.7% of its estimated spending on non-insulin diabetes drugs. GLP-1s accounted for 16.1% of standardized use in the same category.

How Croatia measured use and spending

The researchers counted use in defined daily doses and estimated spending using listed prices. GLP-1 use reached 15.99 daily doses per 1,000 residents in 2024. The whole drug category reached 99.36.

Published estimates cannot show what an insurer paid after discounts. The rules for US GLP-1 insurance coverage show how the reason for prescribing can affect payment. The Croatian totals do not isolate spending on weight management.

How many Australian adults met the criteria?

The Australian eligibility analysis explains how the authors applied treatment criteria to survey respondents. The estimates describe potential eligibility rather than the number of prescriptions filled.

Researchers applied approved prescribing criteria to Australian survey data from 2022 [2]. They estimated that 39.7% of adults met the criteria for long-term weight management, or about 7.8 million. Up to about 339,000 also met the cardiovascular criteria. These figures measure eligibility. They do not track prescriptions, public coverage or spending.

What happened to US medical spending?

A US household survey study estimated spending differences among adults with obesity [3]. Studies of whether GLP-1 drugs reduce healthcare spending separate pharmacy spending from other care. In this study, use was associated with $2,586 less in non-drug medical spending per person-year. Total medical spending was $6,483 higher after adjustment. The study cannot establish what caused the differences or what happens over several years.

Frequently asked

How much did Croatia spend on GLP-1 drugs?
The study estimated €42.07 million in 2024. That was 42.7% of estimated non-insulin diabetes drug spending.
Does the 16.1% figure count prescriptions?
It is the share of drug use measured in defined daily doses. Different prescriptions can cover different amounts and durations.
How many people in Australia met weight-management criteria?
An analysis of 2022 survey data estimated 39.7% of adults, or about 7.8 million. It measured eligibility under approved prescribing criteria.
Were GLP-1 users in the US study associated with lower overall costs?
Total adjusted spending was higher by $6,483 per person-year in this observational study. Non-drug medical spending was lower by $2,586.

Sources

  1. [1] Belančić A, Kučan Štiglić M, Fajkić A, Jelaković A, Pećin I, Reiner Ž (2026). Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia Journal of International Medical Research. PMID 42570295
  2. [2] Castrillon J, et al. (2026). Estimating Eligibility for GLP-1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross-Sectional Analysis of National Health Survey Data The Medical Journal of Australia. PMID 42604458
  3. [3] Çelebi O, et al. (2026). GLP-1 Use, Downstream Medical Spending, and Acute-Care Burden Among Adults with BMI-Defined Obesity: An Overlap-Weighted MEPS Analysis Healthcare. PMID 42588330

Where to get it

The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

See the board →

More in Evidence